ANI Pharmaceuticals: Record Quarter, Cortrophin Guidance Cut — Buy The Dip

ANI Pharmaceuticals delivered a record second quarter and the market punished it for a revised Cortrophin Gel target. Revenue hit $266 million, up 26% year-over-year. Adjusted EPS of $2.21 beat the consensus estimate of $2.04. Adjusted EBITDA of $71.6 million rose 32%, well ahead of analyst expectations. And yet the stock dropped 7.4% on the report and continues to slide, trading at $78.25 on August 8, down 5.3% on heavy volume.

What changed isn't the business trajectory. It's the Cortrophin Gel guidance revision and the market's tendency to treat a trim as a trend reversal. ANI cut its full-year Cortrophin revenue target from $540–$575 million to $520–$540 million. That is a meaningful step down from the prior range. But it still represents 50–55% growth over 2025's $348 million. The market is pricing a deceleration story into a company that just reported record revenue, record EBITDA, and 43% growth in its flagship product. The valuation reset has run ahead of the actual business impairment.

What the quarter actually showed

Cortrophin Gel is still the main engine. Q2 revenue of $117.1 million was up 43% year-over-year and up 56% sequentially from Q1's $75.1 million. The sequential jump is the more telling number — it shows momentum is accelerating, not fading. Growth came from existing specialties: nephrology, neurology, ophthalmology, pulmonology, and rheumatology.

The guidance cut traces back to first-half underperformance, not a second-quarter collapse. Q1 was weighed down by insurance re-verification issues that ANI has since resolved, though the company confirmed some patients were permanently lost. The Q1 disruption set the half-year total below what management initially projected, forcing the annual target lower. Importantly, management said back-half expectations remain largely intact. That means the H2 Cortrophin run-rate needs to land near $201–$212 million across Q3 and Q4, which is only modestly above Q2's $117.1 million on a per-quarter basis.

Generics held up at $99.1 million, up 10% year-over-year, with 12 new product launches year-to-date and at least 15 planned for 2026. That's not glamorous growth, but it's a stable base that funds the rare-disease push. ILUVIEN dipped 16% to $18.7 million due to timing of international shipments — a blip, not a demand shift. Positive six-month topline data from the Phase 4 SYNCHRONICITY trial in chronic non-infectious uveitis was announced, with detailed results expected at a medical conference in Q4 2026.

The gout expansion: real demand or unfunded narrative

This is the centerpiece of the growth story going forward. ANI executed its largest rare-disease sales force expansion in company history, growing the team by 50% to approximately 180 representatives targeting podiatrists and primary care physicians for acute gouty arthritis flares. The target market is roughly 285,000 patients.

The early indicators are actually good. More than 95% of the new reps generated multiple new patient cases. Over a third of prescribers have initiated two or more cases. Demand is balanced between podiatrists and primary care. These numbers suggest genuine clinical interest rather than a soft launch.

But the economics are still unproven. Gout contributed limited revenue in Q2, and management acknowledged that the first fully loaded quarter of gout expansion expenses will hit in Q3, dragging adjusted EBITDA down sequentially. SG&A jumped 20% year-over-year to $80.7 million, and adjusted operating margin contracted to 19.5% in Q2, down 6.1 percentage points from the prior year. The long-term average adjusted operating margin over the last five years has been 24.5%.

The gout expansion is the kind of move that can work spectacularly or eat into margins for quarters while management talks about patience. The early adoption numbers lean toward the former, but the financial impact won't be visible until Q3 and Q4. Investors need to watch Q3 Cortrophin revenue closely — that's the first real data point on whether the gout push is converting to meaningful sales.

Margins under pressure

Gross margin declined 230 basis points to 62.6% on a non-GAAP basis, down from 64.9% a year ago. The decline comes from product mix — higher sales of royalty-bearing products (Cortrophin Gel and a partnered generic launch that commenced in Q3 2025) carry lower margins, and Prucalopride revenues didn't recur. The Harmony Agreement milestone revenue of $8 million helped offset the mix shift, but an additional $2 million in milestone revenue expected in Q3 won't repeat quarterly.

Full-year 2026 adjusted non-GAAP gross margin is guided at 59.9%–60.9%, which would be a further decline. That's the trade-off of a business transitioning from generic-scale volume to specialty-margin products with royalty share-outs and higher SG&A. The question isn't whether margins are compressing — they are. The question is whether revenue growth outpaces the compression enough to keep EBITDA expanding. At $285–$300 million guided for adjusted EBITDA, that would be a 24–31% increase over 2025's $230 million. The math still works.

Valuation: the cheap-enough bridge

At $78.25, ANI trades at 19.7x trailing earnings, 2.26x EV/sales, and 17.1x EV/EBITDA. Free cash flow for the trailing twelve months is $167.5 million, up 60% year-over-year, with an FCF margin of 19.8%. The price-to-free-cash-flow ratio of 9.5x is striking for a company growing revenue at 31% and FCF at 60%.

The stock has fallen from its 52-week high of $99.50 to its current level — a 21.5% decline. The 52-week low is $70.15, so the stock is sitting roughly 12% above its yearly floor. The forward P/E of 38.4x tells you the market still expects significant 2027 earnings growth, but the trailing metrics suggest the current price is doing heavy lifting to absorb the Cortrophin guidance disappointment.

Free cash flow of $167.5 million against a market cap of $1.8 billion gives an FCF yield of 9.3%. That's the kind of cash generation that supports a specialty pharmaceutical business expanding into new indications, even with the gout expenses loading up in the near term. The company has $360 million in unrestricted cash and a net leverage ratio of 1.0x, plus a $100 million share repurchase program authorized through May 2029.

The risks that matter

The IQVIA data discrepancy is worth sitting with. ANI acknowledged a disconnect between its reported revenues and broader IQVIA market data, raising questions about script-to-revenue conversion. Not every prescription written for Cortrophin Gel is turning into recognized revenue. That could reflect insurance coverage friction, patient access barriers, or payer-level resistance. The Q1 insurance re-verification issues were resolved, but the permanent patient losses suggest these problems have lasting effects. Management also flagged potential competitive pressures and gross-to-net dynamics without disclosing specifics. That's the kind of vagueness that keeps skeptics awake.

ILUVIEN is a declining revenue stream. The $18.7 million in Q2 revenue, down 16%, reflects international shipment timing rather than structural failure, but the product isn't a growth driver. The Q4 2026 SYNCHRONICITY trial data is the next catalyst for the ILUVIEN story.

Q3 will be a weak EBITDA quarter due to the fully loaded gout expansion costs and lower Harmony milestone revenue. That sequential decline could trigger another dip if investors overreact to one quarter of loaded expenses in a multi-year growth investment.

The rating

The Cortrophin Gel guidance cut is real, but it's not a trend reversal. H1 was disrupted by solvable insurance issues. Q2 was a record with 56% sequential growth. The gout expansion shows strong early adoption signals. Full-year revenue guidance of $1.08–$1.14 billion was reaffirmed, implying 26% growth on the midpoint. The stock has sold off 21.5% from its 52-week high while the underlying growth story — albeit revised lower from an overly optimistic ceiling — remains intact.

At 19.7x trailing earnings, 17.1x EV/EBITDA, and a 9.3% FCF yield, the valuation has absorbed enough disappointment to create a defensible entry point. The cheap-enough bridge holds: the business has visible risks, but the multiple has already reflected a lot of bad news relative to what actually changed.

The catalyst clock is straightforward. Q3 earnings in November will show the first meaningful revenue impact from the gout expansion and the first fully loaded quarter of its expenses. If Cortrophin hits near $120 million for the quarter — roughly flat with Q2 — the gout ramp is working and the back-half Cortrophin target of $520–$540 million is achievable. If it falls short, the growth narrative needs more time and the stock could revisit its $70 low.

The Q4 2026 SYNCHRONICITY trial data for ILUVIEN is a secondary catalyst that could unlock optionality in the retina franchise.

Rating: Buy. The selloff is pricing a structural Cortrophin slowdown that the operating data doesn't support. The gout expansion has early evidence behind it, full-year growth guidance stands at 26%, and free cash flow is growing at 60%. The stock at $78 offers a risk/reward setup where the multiple has compressed faster than the business has deteriorated. The key metric to watch is Q3 Cortrophin revenue and whether the gout push converts prescriptions into recognized sales.